Overview
Immorta Bio is a preclinical-stage longevity biotechnology company developing senescent cell immunotherapies and personalized stem cell treatments to address fundamental mechanisms of biological aging. The company's dual-platform approach combines SenoVax™, a first-in-class senolytic immunotherapy designed to eliminate aging cells and restore immune surveillance, with StemCellRevivify™, which utilizes personalized mesenchymal stem cells and progenitor cells to restore regenerative capacity. Immorta Bio targets multiple age-related pathologies including cancer, organ failure, neurodegeneration, and inflammatory diseases through mechanisms that address cellular senescence, stem cell exhaustion, and chronic inflammation.